EW
LGND icon

Evoke Wealth’s Ligand Pharmaceuticals LGND Stock Holding History

Evoke Wealth’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-351
Closed -$21.8K – 1366
2019
Q3 		$21.8K Buy
+351
New +$22K ﹤0.01% 634

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Evoke Wealth's LGND Position: Q4 2019 in Review

Evoke Wealth sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 351 shares — an estimated $21.8K sold.

Evoke Wealth first reported a position in LGND in Q3 2019 and held it in 1 quarter. The position peaked at $21.8K in Q3 2019. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

  • Evoke Wealth reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Evoke Wealth sold 351 Ligand Pharmaceuticals shares in Q4 2019, an estimated $21.8K.
  • Evoke Wealth first reported a position in Ligand Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Evoke Wealth's Ligand Pharmaceuticals position peaked at $21.8K in Q3 2019.
  • 266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Evoke Wealth's 13F filing for Q4 2019, filed 7 Feb 2020.